Toll-like receptor 5 (TLR5) is considered an attractive target for anticancer immunotherapy. TLR5 agonists, bacterial flagellin and engineered flagellin derivatives, have been shown to have potent antitumor and metastasis-suppressive effects in multiple animal models and to be safe in both animals and humans. Anticancer efficacy of TLR5 agonists stems from TLR5-dependent activation of nuclear factor-κB (NF-κB) that mediates innate and adaptive antitumor immune responses. To extend application of TLR5-targeted anticancer immunotherapy to tumors that do not naturally express TLR5, we created an adenovirus-based vector for intratumor delivery, named Mobilan that drives expression of self-activating TLR5 signaling cassette comprising of human TLR5 and a secreted derivative of Salmonella flagellin structurally analogous to a clinical stage TLR5 agonist, entolimod. Co-expression of TLR5 receptor and agonist in Mobilan-infected cells established an autocrine/paracrine TLR5 signaling loop resulting in constitutive activation of NF-κB both in vitro and in vivo. Injection of Mobilan into primary tumors of the prostate cancer-prone transgenic adenocarcinoma of the mouse prostate (TRAMP) mice resulted in a strong induction of multiple genes involved in inflammatory responses and mobilization of innate immune cells into the tumors including neutrophils and NK cells and suppressed tumor progression. Intratumoral injection of Mobilan into subcutaneously growing syngeneic prostate tumors in immunocompetent hosts improved animal survival after surgical resection of the tumors, by suppression of tumor metastasis. In addition, vaccination of mice with irradiated Mobilan-transduced prostate tumor cells protected mice against subsequent tumor challenge. These results provide proof-of-concept for Mobilan as a tool for antitumor vaccination that directs TLR5-mediated immune response toward cancer cells and does not require identification of tumor antigens.
INTRODUCTION
Toll-like receptors (TLRs) are major regulators of innate and adaptive immunity and are gaining increasing attention as potential targets for preventing and treating cancer. In particular, pharmacological activation of TLR5 by its natural agonist flagellin or engineered agonists 1 has been shown to stimulate antitumor immune responses in multiple animal tumor models [2] [3] [4] [5] [6] [7] and models of liver metastasis. 5, [8] [9] [10] [11] These therapeutic effects stem from ligand-induced TLR5 signaling leading to MyD88-dependent activation of nuclear factor-κB (NF-κB) and subsequent transcriptional induction of numerous genes related to inflammation and host defense. 12, 13 Similar to agonists of other TLRs, flagellin activates innate immune cells that induce maturation and chemokine production in dendritic cells [14] [15] [16] and stimulates CD4 + T cells to produce interferon-γ, interleukin (IL)-8 and IL-10, but not IL-4. These cytokines can promote a Th1-type response and are beneficial for generating efficient CD8 + T-cell responses. It was found that antitumor activity of flagellin was associated with mobilization of different classes of immune cells, in particular, neutrophils and NK cells leading to stimulation of CD8 + T-cell responses. 6, 9, 10 TLR5 agonists are promising anticancer agents because of their safety, as well as their efficacy. Unlike many other TLRs, TLR5 signaling, while immunostimulatory, does not induce certain highly pro-inflammatory cytokines that can cause a self-amplifying and potentially dangerous 'cytokine storm'. [17] [18] [19] The safety of TLR5 agonists is supported by the results of two clinical studies in which 4150 healthy subjects and cancer patients were administered the flagellin derivative entolimod (previously CBLB502), which is being developed for tissue protective and anticancer applications (https://clinicaltrials.gov/ct2/show/NCT02654938).
Antitumor/metastatic efficacy of TLR5 agonists correlates not only with TLR5 expression by the tumor itself 3, 4, 6 but also with TLR5 expression in the tumor microenvironment (for example, suppression of liver metastasis of TLR5-negative tumors). 8 Here we introduce a strategy to increase the range of tumors that may be effectively treated via TLR5 agonist-dependent immunotherapy. An adenovirus-based construct (Mobilan-VM3 or M-VM3) was generated to direct co-expression of TLR5 and a secreted variant of entolimod with the expectation that delivery of the construct to a tumor would establish potent autocrine/paracrine TLR5 activation regardless of the tumor's natural TLR5 expression status. We hypothesized that Mobilan-driven TLR5 signaling within a tumor would stimulate innate immune responses capable of suppressing primary tumor growth and also providing long-term protection against metastases and recurrent tumors.
To test this approach, we focused on prostate cancer after finding that most prostate cancers express the Coxsackie virus and adenovirus receptor (CAR) 20 required for efficient infection by serotype 5 adenovirus-based vectors such as Mobilan.
Prostate cancer is extremely common, with a 14% lifetime risk of diagnosis for American men, and remains the second leading cause of cancer death in this demographic group. 21 Therefore, development of new, more effective treatments for prostate cancer is critical. Our hypothesis that Mobilan may address this need is supported by the efficacy of several other immunotherapeutic approaches against prostate cancer. These include cellbased vaccines (Sipuleucel-T, BPX-101, DCVAC/Pa, GVAX), [21] [22] [23] [24] [25] [26] virus-based vaccines (PROSTVAC-VF) 27, 28 and antibodies against immune checkpoint proteins (CTLA-4, PD1/PD-L1). [29] [30] [31] [32] [33] [34] [35] [36] However, none of these strategies were found to extend survival for more than a few months.
For our studies with Mobilan-VM3, we used the well-known transgenic adenocarcinoma of the mouse prostate (TRAMP) model, [37] [38] [39] which has been widely adopted to evaluate candidate therapies. [40] [41] [42] In this model, expression of the large and small SV40 tumor antigens from the prostate-specific rat probasin promoter leads to spontaneous development of epithelial hyperplasia in the prostate by 8 weeks of age and then to malignant adenocarcinomas. 43 Infection of TRAMP prostate tumor cells with M-VM3 established expression of both TLR5 and secreted entolimod as expected and induced activation of NF-κB in vitro and in vivo. Intraprostate tumor injections of M-VM3 in TRAMP mice led to strong induction of inflammatory genes, mobilization of innate immune cells into tumors and signs of tumor atrophy. Further support for use of Mobilan against prostate cancer was provided by results showing that intratumoral (i.t.) injection of M-VM3 into subcutaneous (s.c.) prostate tumors improved animal survival after surgical resection of the tumors (that is, suppressed tumor metastasis) and that vaccination of mice with irradiated M-VM3-infected prostate tumor cells protected mice against tumor challenge.
RESULTS

Generation and characterization of Mobilan vectors
In the very first variant of Mobilan, Mobilan-0 (M-0), a bi-cistronic expression cassette that directs constitutive expression of full-length human TLR5 from the cytomegalovirus promoter and a secreted version of the flagellin-based TLR5 agonist CBLB502 (CBLB502s) 44 from the EF1 promoter ( Figure 1A(a) ) was cloned into a nonreplicating adenoviral vector (pDC515/ pBHGloxΔE1,3 Cre). Western blotting confirmed production of both hTLR5 and CBLB502 proteins by M-0-infected TLR5-negative MOSEC murine ovarian cancer cells ( Figure 1B) . However, CBLB502s produced in these cells had a larger apparent size on the blots than expected and its specific activity (ratio of CBLB502s amount measured by ELISA and its NF-κB-activating capacity in HEK293-NF-κB-lacZ reporter cells) was onlỹ 1% of that observed for CBLB502 produced in Escherichia coli. The presence of four predicted glycosylation sites in the amino-acid sequence of CBLB502 suggested that CBLB502s produced in mammalian cells may be inactive because of glycosylation. Indeed, treatment of lysates of M-0-infected MOSEC cells with deglycosylating enzymes resulted in a shift in the mobility of CBLB502s to the expected size ( Figure 1B(b) ). A 'non-glycosylated' mutant version of CBLB502 (CBLB502NQ) containing asparagine to glutamine substitutions in all four predicted glycosylation sites was produced in E. coli and found to have similar specific activity in HEK293-NF-κB-lacZ reporter cells to CBLB502 ( Figure 1C ). After generation and testing of a series of Mobilan versions with CBLB502NQ TLR5 agonist, an optimized adenoviral construct (named Mobilan-VM3 or M-VM3) was generated that expresses balanced levels of CBLB502NQs and hTLR5 from the UbiC promoter and cytomegalovirus promoter, respectively ( Figure 1A(b) ). Control adenoviral construct expressing red fluorescent protein mCherry was also generated ( Figure 1A(c) ). The specific activity of CBLB502NQs produced in M-VM3-infected MOSEC cells was similar to that of the E. coli-produced CBLB502 ( Figure 1D) ; this was likely because of partial degradation of CBLB502NQs during expression ( Figure 1E ).
Establishment of fully functional autocrine/paracrine TLR5 signaling in the cells transduced with M-VM3 was demonstrated in TLR5-negative MOSEC cells (non-responsive to entolimod, Supplementary Figure S1 ) using nuclear translocation of the p65 subunit of NF-κB as an indicator of its activation ( Figure 1F ). M-VM3 infection also led to p65 nuclear localization in hepatocyte cultures from TLR5KO mice (Supplementary Figure S1) . We also tested functionality of M-VM3 in the TRAMP-C2 prostate cancer cell line established from a primary TRAMP mouse prostate tumor. 37 TRAMP-C2 cells were stably transfected with an NF-κB reporter construct and then infected with M-VM3 or a control adenovirus directing cytomegalovirus promoter-driven red fluorescent protein expression (Ad-mCherry). Dose-dependent NF-κB activation was observed in the M-VM3-infected TRAMP-C2 cells ( Figure 1G ).
One potential limitation for clinical use of TLR5 agonists is preexistence of a prohibitively high level of anti-flagellin neutralizing antibodies in~10% of humans (CBLI, unpublished), likely because of exposure to flagellated enterobacteria of the gut microflora. However, we found that anti-flagellin neutralizing antibodies did not significantly affect M-VM3-directed TLR5 signaling in MOSEC-NF-κB-luciferase reporter cells ( Figure 1H ) even with antibody levels 10-fold higher than that required to neutralize CBLB502NQs added to the medium of TLR5-positive HEK293-NF-κB-lacZ reporter cells (Supplementary Figure S2) . These results suggest that in M-VM3-infected cells, TLR5 interacts with CBLB502NQs during co-secretion and the complex is either inaccessible to or cannot be disrupted by neutralizing antibodies. Resistance of M-VM3-induced TLR5 signaling to neutralizing antibodies would allow its therapeutic use in a wider human population compared with entolimod. Table S3 ) representing 23 different tumor types and 12 different normal tissues, we divided tumor types into three categories: (i) low CAR expression (hematopoietic, soft tissue, skin, head and neck, brain, cervical, breast, and esophageal tumors); (ii) high CAR expression (bladder, prostate cancer, small intestine, thyroid, testicular and colon tumors); and (iii) mid-range CAR expression (lung, ovary, stomach, kidney, melanoma, liver, endocrine and mesothelioma tumors). We then focused on prostate tumors and analyzed CAR expression using tissue microarray containing 134 prostate cancer-derived and 134 normal prostate-derived samples. In all, 90% of all prostate samples (regardless of normal or cancerous) were found to be strongly CAR positive (Figure 2a ). High CAR expression was also detected in TRAMP-C2 murine prostate cancer cells (Figure 2b ). These observations suggest that M-VM3 treatment could be effective in the vast majority of prostate cancer patients, as well as in the prostate tumors in TRAMP mice.
To confirm the latter expectation, we injected Ad-mCherry (5 × 10 8 v.p./tumor) directly into TRAMP mouse prostate tumors Mobilan induces constitutive activation of NF-κB in transduced cells Self-activating TLR5 cassette transduced by Mobilan is expected to generate constitutive activity of the TLR5 pathway because of constant intrinsic stimulation by the interaction of co-expressed TLR5 and its ligand. We expected that the dynamic of M-VM3-driven TLR5-mediated activity will be different from that induced by stimulation with extrinsically applied TLR5 agonist, which is known to be transient because of TLR5 depletion and negative feedback mechanisms of NF-κB regulation. Cultures of mouse hepatocytes carrying an NF-κB-dependent luciferase reporter were either transduced with M-VM3 or treated with entolimod added to the medium and the activity of reporter was constantly monitored during 2 days using LumiCycle ( Figure 3a ). As expected, in vitro treatment of hepatocytes with entolimod resulted in rapid but transient NF-κB activation. In contrast, the dynamic of NF-κB activation in response to M-VM3 was slower but reached similar levels and stayed stably high during the whole observation period, thus demonstrating the desirable and planned activity of M-VM3.
To examine M-VM3 functionality in the whole-animal setting, we compared NF-κB activation in Balb/C-Tg(IκBα-luc)Xen NF-κB Self-activating TLR5 cassette for cancer immunotherapy V Mett et al reporter mice treated with M-VM3 or entolimod. Whole-body bioluminescence imaging of these mice at 3, 24 and 48 h after intraprostate injections showed that entolimod induced rapid NF-κB activation in the liver area (at 3 h), which diminished by 24 h. In contrast, M-VM3 activated NF-κB slowly in the lower abdominal area (at 24 h) and this persisted during the whole observation period (48 h) (Figure 3b ). NF-κB-driven luciferase expression was measured in lysates of liver, intestine and prostate prepared from reporter mice 48 h after M-VM3 intravenous or intraprostate injections (Figure 3c ). Intravenous M-VM3 resulted in strong NF-κB activation in the liver, lesser activation in the intestine, and no significant activation in the prostate. In contrast, intraprostate M-VM3 injection caused significant NF-κB activation in prostate tissue, some activation in intestine and no substantial activation in liver. These results show lack of systemic leakage of functional amounts of TLR5 agonist from the transduced site (what otherwise would be detected by NF-κB activation in the liver).
Our findings that M-VM3 is capable of establishing continuous TLR5 signaling in cultured cells, as well as in mice, particularly in prostate tissue provide proof-of-concept for the idea behind Mobilan and support the feasibility of using M-VM3 to treat prostate cancer.
Intraprostate M-VM3 injection in TRAMP mice leads to reduced organ weight and mobilization of immune cells into the hyperplastic prostate The ability of M-VM3 to suppress prostate tumor progression in the TRAMP model was tested by administering M-VM3, AdmCherry or phosphate-buffered saline (PBS) to 12-week-old mice by intraprostate injection. Six weeks later, mice were evaluated for Table S1 ). Consistent with the known mechanisms of activation of TLR5 signaling by entolimod, this list includes several NF-κB target genes such as CXCL1, IL1B and S100A9. At 48 h, there was a larger number of genes specifically upregulated by M-VM3-versus Ad-mCherry (57 genes, Supplementary Table S2) . This list includes a number of genes encoding cytokines/chemokines (IL1B, CCL7 and 9, CXCL9, 13 and 17), which may have roles in mobilization of immune cells into tumors. Other notable M-VM3-specific induced genes are several with known roles in regulation of NF-κB responses (for example, IKBKE and NFKBIZ) or antiviral activity (for example, NLRC5 and OASL1). Only four genes induced at 24 h remained induced at 48 h (NLRC5, CLEC4A1, IL1B and S100A9). In particular, M-VM3-induced NLRC5 may contribute to the antitumor immune response and prevention of tumor immune escape through activation of expression of MHC class-I molecules and components of the antigen-processing machinery. 45 Intratumoral delivery of M-VM3 stimulates an innate immune response To characterize immune cell infiltration into TRAMP prostate tumors in response to M-VM3, TRAMP mice with palpable prostate tumors were given an i.t. injection of PBS, Ad-mCherry or M-VM3 and prostate tumors and tumor-draining lymph nodes were collected 2 or 7 days later. As activation of TLR5 stimulates recruitment of neutrophils, NK cells and T cells to the liver, 6,8-10 we sought to characterize similar immune cell profiles in TRAMP prostate tumors by fluorescence-activated cell sorting analysis. Neutrophils were significantly recruited to the prostate on day 2 after i.t. delivery of M-VM3 or, to a lesser extent, after Ad-mCherry (Figure 5a ). Although M-VM3 appeared to stimulate stronger recruitment of neutrophils than Ad-mCherry, this difference did not reach statistical significance. NK cells also responded to M-VM3, but not to Ad-mCherry and with kinetics that was different than for neutrophils and that was dependent upon virus identity (Figure 5b ). M-VM3-specific induction of NK cells was not observed until day 7 post-i.t. injection.
We next characterized the response of adaptive immunity, which included CD8 + and CD4 + T cells. Levels of CD8 + T cells in TRAMP tumors did not change following i.t. delivery of either AdmCherry or M-VM3 on day 7 (Figure 5c ). Similar to the CD8 + T-cell response, bona fide CD4 + T cells, which we characterized as lacking FoxP3 expression and thus not Treg, showed no statistical difference at day 7 post-i.t. injection (Figure 5d) . Finally, the effect of i.t. viral delivery on immunosuppressive Treg was characterized in TRAMP tumors and tumor-draining lymph node on day 7 post-i.t. injection. Levels of Tregs in TRAMP tumors (Figure 5e ) and tumor-draining lymph nodes (Figure 5f ) were not significantly affected by either virus.
Together, these data indicate that i.t. adenovirus (M-VM3 or AdmCherry) injection in TRAMP mice leads to recruitment of components of innate immunity to the prostate while having no impact on immunosuppressive Tregs. The main M-VM3-specific response was recruitment of NK cells to the prostate and, to a lesser extent, neutrophil recruitment.
Effect of M-VM3 on prostate tumor metastasis model M-VM3 anti-metastatic activity was tested in a model in which metastatic outgrowth of TRAMP-C2 prostate cancer occurs after primary tumor resection. 46 Mice with s.c. growing TRAMP-C2 tumors (~100 mm 3 ) were given a single i.t. injection of PBS, AdmCherry or M-VM3. Primary tumors were removed 7 days postinjection and the animals were monitored for survival until day 150 post-injection. As shown in Figure 6a , M-VM3 injection before tumor removal improved survival to day 150 compared with PBS and Ad-mCherry. Log-rank analysis showed that the difference in mortality kinetics between the M-VM3-treated and control groups was nearly statistically significant (P = 0.06). These results indicate that M-VM3 has a potential to be effective in combination with surgery to prevent prostate tumor metastasis. 
DISCUSSION
Immunotherapeutic strategies aimed at stimulating the immune system to attack cancer cells or blocking immunosuppressive mechanisms hold strong promise for improving cancer treatment. Our work and that of others has identified TLR5 activation as a particularly attractive means to stimulate antitumor immune responses (reviewed in Introduction). [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] To expand clinical Self-activating TLR5 cassette for cancer immunotherapy V Mett et al applications of TLR5-mediated immunotherapy to include tumors that do not naturally express TLR5, we generated a novel adenoviral vector, Mobilan-VM3, which directs co-expression of TLR5 and a secreted entolimod-based TLR5 agonist and thereby expected to establish intrinsic TLR5 activation in transduced tumor cells localized and restricted to the injection site.
The ability of Mobilan to overcome the natural mechanisms that shut down TLR5 signaling consequently limit the immunostimulatory ability of extrinsically applied TLR5 agonists, like entolimod, was demonstrated using an NF-κB reporter system in cell culture and in vivo. In both cases, Mobilan was capable of maintaining greater constitutive and higher NF-κB signaling than entolimod. One more important advantage of Mobilan is the resistance of its activity as a TLR5 activator to neutralizing antibodies, which completely abolish the activity of entolimod, and prevent a significant proportion of the human population from the benefits offered by treatment with this agent.
Prostate cancer models were used for in vivo testing as a prospective clinical target disease for Mobilan. This choice has been made based on several considerations. First, a high frequency of CAR expression in normal and cancerous prostate epithelium shown in the present work is consistent with previous demonstration of efficient infection of prostate tumors by adenoviruses; 47 we confirmed efficient transduction of mouse prostate tumors (in vivo) and surgical specimens of human prostate tumors (ex vivo) upon direct i.t. injection of our adenoviral vectors. Second, the prostate is relatively easily accessible for intraorgan injection with Mobilan, allowing us to develop a clinically translatable treatment protocol. Third, prostate does not belong to the group of organs with high expression of TLR5; therefore, Mobilan has the opportunity to induce TLR5 signaling in TLR5-negative organs, which are not among the targets of entolimod. Also, the efficacy of type 5 adenovirus infection of cells depends on the level of CAR receptor expression on their surface. Cells of hematopoietic origin that do not express CAR cannot be transduced with vectors based on a type 5 adenovirus. 48 One of the biggest concerns about systemic use of TLR agonists is their safety. Acute systemic inflammatory response induced following systemic administration of TLR agonists has prevented development of a variety of TLR agonists into approved drugs. 49 And the only one currently approved by the FDA, imiquimod, is allowed exclusively for topical applications. 50 We hoped that the level of TLR5 agonist expression by Mobilan-VM3 would prevent this safety concern by producing a sufficient amount of agonist for intrinsic TLR5 signaling activation but not enough for systemic effects. In fact, unlike entolimod treatment, M-VM3 established continuous local (but not systemic) TLR5 signaling in TRAMP prostate cancer cells and in mouse prostate tissue following intraprostate injection. These results highlight another important advantage of Mobilan-its localized activity restricted to the injection site.
Efficacy of TLR5 agonists as antitumor immunotherapeutic agents has been demonstrated in multiple preclinical models. The antitumor activity of flagellin in mice bearing breast cancer xenografts was associated with increased tumor necrosis and enhanced infiltration of neutrophils into tumors. 6 Entolimoddriven recruitment of NK cells to the liver was shown to be critical for the antitumor efficacy of the drug in murine tumor models. 8, 10 It was previously shown in TLR5-positive human prostate cancer cell lines LNCaP and DU-145 that flagellin induces chemokines that recruit NK cells and cytotoxic CD8 + T cells, which may contribute to tumor inhibition. 51 Leigh et al. 52 demonstrated that activity of entolimod against lymphoma involved NK and CD8 + T cells. In murine colon and mammary metastatic cancer models, entolimod supported homing of NK cells to the liver followed by NK cell-dependent activation of dendritic cells and antitumor CD8 + T-cell responses. 9 We expected Mobilan to utilize all these antitumor mechanisms in a localized organ-specific setting. In fact, injection of M-VM3 into TRAMP prostate tumors suppressed tumor progression (indicated by tumor weight and histology) and led to recruitment of innate immunity, including neutrophils and NK cells. Involvement of these immune mechanisms can be explained by the profile of M-VM3-specific gene expression observed in our microarray experiments and is consistent with earlier studies with flagellin and entolimod. Remarkably, indications of antitumor efficacy of M-MV3 in the TRAMP model was demonstrated even with no detectable increase in T cells, suggesting that the therapeutic effect is driven predominantly by an innate immune response. It remains unclear whether lack of T-cell engagement is a property of the model or the prostate as an organ.
Potential use of TLR5 agonists to stimulate antitumor immune responses is supported by studies evaluating flagellin as a vaccine adjuvant. Co-administration of flagellin with MHC class II-restricted P10 53 or E6/E7 peptides 54 or with an adenovirus expressing the MUC-1 tumor antigen 55 led to improved antitumor effects of the vaccines. Beneficial effects of flagellin were also observed in the contexts of an adenovirus expressing a chaperone Grp170-flagellin chimera, 56 liposomes engrafted with flagellin-derived peptides and containing the model antigen ovalbumin, 57 and tumor cells 2, 21 and T cells 58 engineered to express flagellin. In our study, a single i.t. injection of M-VM3 into s.c. growing TRAMP-C2 tumors improved mouse survival after surgical removal of the tumors, suggesting that i.t. vaccination with M-VM3 may be an effective strategy for preventing metastasis in prostate cancer patients. We also found that vaccination of mice with lethally irradiated M-VM3-infected TRAMP-C2 cells (prime + 2 boosts) protected mice against a subsequent s.c. challenge with TRAMP-C2 cells. Use of cell-based vaccination against prostate cancer is illustrated by Sipuleucel-T, an FDA-approved autologous cellular vaccine consisting of a patient's dendritic cells loaded with a prostatic acid phosphatase-granulocyte/macrophage colonystimulating factor fusion protein. 21 Sipuleucel-T prolonged survival in men with metastatic prostate cancer but had no effect on time to progression. 59 Trials with GVAX, a vaccine comprised of prostate cancer cell lines (LNCaP and PC3) expressing GM-CSF were terminated because of a lack of overall survival benefit. [21] [22] [23] [24] Our data suggest that M-VM3 could fill the need for more effective cell-based vaccines against prostate cancer. The first step in this direction is an ongoing Phase I clinical trial, in which M-VM3 is used for intraprostate injection 2 weeks before radical prostatectomy (ClinicalTrials.gov Identifier: NCT02654938). Future work will address the possibility of achieving greater antitumor effects by combining M-VM3 with immune checkpoint inhibitors (CTLA-4, PD1/PD-L1) that have shown activity against different tumors. [29] [30] [31] [32] [33] [34] [35] [36] Overall, this work provides proof-of-concept for use of M-VM3 to establish constitutive TLR5 signaling in tumors regardless of their TLR5 expression status and demonstrates that such signaling leads to antitumor immune responses capable of suppressing prostate tumor development, progression and metastasis in different experimental settings. CBLB502 and CBLB502NQ were produced as described. 60 Cultured cells
MATERIALS AND METHODS Mice
The TRAMP-C2 prostate cancer cells maintained as described. 37 To develop stable NF-κB-luc reporter cell lines, MOSEC cells (from Dr A Odunsi, RPCI, Buffalo, NY, USA) and TRAMP-C2 cells were transduced with Lenti NF-κB Reporter (QIAGEN, Frederick, MD, USA) followed by puromycin selection. Primary mouse hepatocytes were isolated as described. 61 All cell lines were tested for mycoplasma contamination (MycoAlert Mycoplasma Detection assay, Lonza, Rockland, ME, USA). No authentication of the cell lines was conducted by the authors.
Adenoviruses
Adenovirus constructs (Ad-mCherry, Mobilan M-0 and M-VM3) were prepared using the AdMax system (Microbix Biosystems, Mississauga, Canada). Expression cassettes were assembled in shuttle plasmid pDC515 and Ad genomic plasmid pBHGloxΔE1,3 Cre was used for recombination to obtain final constructs. Resulting viruses were plaque-purified, amplified and purified in CsCl gradient. Mobilan M-0, M-VM3 and Ad-mCherry stocks contained 1 × 10 12 , 1.1 × 10 12 and 1 × 10 12 vp/ml, respectively.
Luciferase assays NF-κB-dependent luciferase expression in reporter cell lines and in extracts of reporter mouse organs was measured as described in references Yoon et al. 60 and Burdelya et al., 44 respectively.
Imaging of NF-κB-driven luciferase expression in live mice
Three-month-old males of Balb/C-Tg(IκBα-luc)Xen NF-κB reporter mice were used. Bio-luminescence imaging was performed using the IVIS50 imaging system (PerkinElmer, Waltham, MA, USA) as described. 44 
NF-κB-driven luciferase expression in live cells
Mouse NF-κB-luc-hepatocytes were infected with M-VM3 or Ad-mCherry (multiplicity of infection (MOI) = 10 4 ) or treated with entolimod (0.1 μg/ml) or PBS. The virus-containing medium was replaced with fresh medium after 3 h (1 h in case of entolimod) and luciferin was added to the cells. Luciferase activity was measured in LumiCycle 32 (Actimetrics, Wilmette, IL, USA) for 3 days. Baseline level of luciferase activity was subtracted.
ELISA and western blot CBLB502 and its derivatives were detected by ELISA 62 and western blot using CBLB502-specific pAbs and TLR5 was detected by western blot using 1B04 mAb (see Reagents).
Histochemistry and immunohistochemistry
Sections of tumor tissues and cultured cells were stained as described. 44 Primary antibodies: anti-NF-κB p65 (Abcam, cat. #7970), anti-cytokeratin 8 (Troma-1; Developmental Studies Hybridoma Bank, University of Iowa), anti-CAR (Santa Cruz, cat.#sc-15405) and anti-integrin alpha 6 (Abcam, cat. #ab62844-100). Images were obtained using an Axio Imager Z1 (Carl Zeiss, Jena, Germany) fluorescent microscope equipped with a high sensitivity CCD digital camera MRm (Carl Zeiss, Jena, Germany) and AxioVision software (release 4.8.3) (Carl Zeiss, Jena, Germany). Individual, manual scoring of tissue microarray samples was performed using the ImageScope image viewer from Aperio (Aperio Technologies, Vista, CA, USA). Intensity was recorded/scored in a semiquantitative manner. 63 Evaluation of blinded histological sections was performed by trained pathologist.
Deglycosylation of CBLB502
MOSEC cultures at 50% confluence were infected with M-0 (1 × 10 9 v.p./ ml). After 48 h, cell extracts were prepared using CelLytic M (SigmaAldrich). Lysates were cleared by centrifugation and desalted using spin columns. Deglycosylation was performed with the Protein Deglycosylation Mix reagent kit (New England Biolabs, Ipswich, MA, USA) according to the manufacturer's protocol.
Infection of mouse and human tumors with Ad-mCherry In total, 1 × 10 7 TRAMP-C2 cells were injected into mice s.c. Ad-mCherry (2 × 10 9 v.p.in total) was injected in three different points of each tumor (~100 mm 3 ). Samples of human prostate tumors (received from RPCI; nonhuman subject research, Protocol NHR028412 approved by DSRG/Tissue Group) were dissected into 0.5 × 0.5 × 1 cm pieces and two pieces from each patient were injected with Ad-mCherry as for mouse tumors. Injected human samples were cultured in enriched Dulbecco's modified Eagle's medium additionally supplemented with 5 μg/ml insulin and 10 − 8 M dihydrotestosterone at 37°C, 5% CO 2 .
Prostate injection
The abdomens of anesthetized TRAMP mice were shaved. Using aseptic technique, a 1 cm incision was made with scissors above the prostate on the ventral side of the animal through the skin and body wall and 10 9 v.p. (50 μl in total) of M-VM3, Ad-mCherry or PBS were injected into three points of the prostate ventral lobe. The body wall was closed with 1-2 sutures and the skin was closed with wound clips. 
Cell-based immunization of mice
Surgical removal of TRAMP-C2 tumors after i.t. injection M-VM3
Tumors (~100 mm 3 ) that developed in C57BL/6 mice 4 weeks after TRAMP-C2 cell s.c. inoculation (1 × 10 7 cells per mouse) were injected i.t. with PBS, Ad-mCherry (10 8 vp) or M-VM3 (10 8 vp) (50 μl/tumor). Tumors were surgically removed 7 days post-injection as described. 46 Fluorescence-activated cell sorting analysis of immune cell populations M-VM3-or Ad-mCherry-or PBS-injected tumors were harvested 2, 7 or 14 days post-injection and weighed. Single-cell suspensions were generated and analyzed by fluorescence-activated cell sorting as described. 44 
Microarray analysis
Gene expression profiling was accomplished by the RPCI Genomics Shared Facility using Mouse WG-6 whole-genome gene expression assay and direct hybridization assay (Illumina, San Diego, CA, USA). RNA was prepared 24 and 48 h after injection with M-VM3, Ad-mCherry (10 9 v.p, 50 μl total into three points) or PBS (two mice per group) into palpable spontaneous prostate tumors of TRAMP mice (22-26 weeks old). Quantile normalization and background subtraction was conducted using Illumina Genestudio. Genes that had a minimum signal of 50 in both adenoviralinfected replicates and were induced at least twofold by Ad-mCherry or M-VM3 as compared with PBS were considered induced for the purposes of analysis.
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Statistical analysis
One representative experimental data set is shown from two or three independent experiments. Differences between groups within experiments were analyzed using two-tailed unpaired Student's t-test and Fisher's exact test. Animal survival Kaplan-Meier curves were compared using log-rank test. Po0.05 was considered statistically significant.
